Join Now

SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY

By Natalie Themm | Published June 25, 2026

Aligns With Growing Focus on Early Identification and Management of Preterm Birth Risk

Posted in BioUtah News | Tagged | Comments Off on SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY

Landmark Study Finds PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications

By Natalie Themm | Published January 8, 2026

Published in the journal PREGNANCY, the PRIME Study demonstrates significant improvements in neonatal outcomes with early risk screening and targeted interventions.

Posted in BioUtah News | Tagged | Comments Off on Landmark Study Finds PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications

Sera Prognostics Announces Pricing of $50 Million Public Offering

By Natalie Themm | Published February 13, 2025

Sera Prognostics Announces Pricing of $50 Million Public Offering

Posted in BioUtah News | Tagged | Comments Off on Sera Prognostics Announces Pricing of $50 Million Public Offering

SERA PROGNOSTICS EXPECTED TO BE ADDED TO RUSSELL 2000 AND 3000 INDEXES

By Natalie Themm | Published May 30, 2024

SERA PROGNOSTICS EXPECTED TO BE ADDED TO RUSSELL 2000 AND 3000 INDEXES

Posted in BioUtah News | Tagged | Comments Off on SERA PROGNOSTICS EXPECTED TO BE ADDED TO RUSSELL 2000 AND 3000 INDEXES

A Special Thanks To Our Legacy and Platinum Elite Members